Unknown

Dataset Information

0

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.


ABSTRACT:

Background

There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus disease (COVID-19), with special concern for those affected by hematological malignancies.

Case presentation

Here, we report the case of a 75-year-old male with chronic lymphocytic leukemia who was deficient in CD19+CD20+ B-lymphocyte populations due to previous treatment with anti-CD20 monoclonal antibodies. The patient presented with severe COVID-19 pneumonia due to prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and was treated with two courses of the antiviral plitidepsin on a compassionate use basis. The patient subsequently achieved an undetectable viral load, and his pneumonia resolved.

Conclusions

Treatment with plitidepsin was well-tolerated without any further hematological or cardiovascular toxicities. This case further supports plitidepsin as a potential antiviral drug in SARS-CoV-2 patients affected by immune deficiencies and hematological malignancies.

SUBMITTER: Guisado-Vasco P 

PROVIDER: S-EPMC8743692 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6485963 | biostudies-literature
| S-EPMC9253383 | biostudies-literature
| S-EPMC11007165 | biostudies-literature
| S-EPMC8310246 | biostudies-literature
| S-EPMC6343614 | biostudies-literature
| S-EPMC2805725 | biostudies-other
| S-EPMC10276018 | biostudies-literature
| S-EPMC9649889 | biostudies-literature
| S-EPMC5334788 | biostudies-literature